Guideline for Gradual Tapering of Chlorpromazine 100 mg at Bedtime

Tapering Protocol

Reduce the nightly dose by 25 % every 2–4 weeks (e.g., 100 mg → 75 mg → 50 mg → 25 mg → discontinue), extending the overall taper to a minimum of 8–12 weeks to lessen withdrawal symptoms such as gastritis, nausea, tremulousness, and movement disorders. 1
For individuals who have been on chlorpromazine for many months or years, extend the taper to 12–16 weeks or longer and use smaller decrements (≈10–20 % of the current dose every 2–4 weeks) to further reduce withdrawal risk. 1
A taper duration longer than 1 month is recommended to minimize discontinuation effects, as reflected in clinical practice guidelines. 1

Conduct weekly assessments for withdrawal manifestations—including nausea, vomiting, dizziness, tremulousness, insomnia, anxiety, and restlessness—especially during the first 1–3 days after each dose reduction. 1
If clinically significant withdrawal symptoms appear, pause the taper at the current dose for an additional 1–2 weeks before attempting further reduction. 1

Incorporate cognitive‑behavioral therapy (CBT) during the taper; evidence shows it improves success rates for medication discontinuation. 1
Provide patient education about expected withdrawal symptoms and the rationale for a gradual taper to enhance engagement and adherence. 1
When insomnia emerges, prioritize sleep‑hygiene counseling rather than adding another sedating medication, to avoid new dependencies. 1

Do not discontinue chlorpromazine abruptly, as this markedly raises the risk of severe withdrawal, including movement disorders and neuroleptic malignant syndrome.
Avoid rapid dose reductions (e.g., >50 % per week); fast tapers increase the likelihood of withdrawal symptoms and possible relapse.
If withdrawal symptoms develop, do not abandon the patient—slow the taper or pause until symptoms resolve. 1
Do not substitute another antipsychotic during the taper unless there is a clear clinical indication for ongoing psychotic symptom control. 1

Minimum taper duration: 8–12 weeks for patients on 100 mg nightly for weeks to months; longer tapers (12–16 weeks or more) are appropriate for prolonged use or high sensitivity to withdrawal. 1
Withdrawal symptoms typically peak within 1–3 days after each dose reduction and usually resolve within 1–2 weeks when the taper is paced appropriately. 1
Successful tapering often requires several weeks to months; the emphasis should be on durability of the taper rather than speed. 1

Gastritis, nausea and vomiting, dizziness, and tremulousness can occur following abrupt discontinuation of high-dose chlorpromazine therapy, as identified by the FDA-approved drug label, in patients undergoing chlorpromazine withdrawal 2
Tremulousness is a withdrawal symptom that can occur following abrupt discontinuation of high-dose chlorpromazine therapy, in patients undergoing chlorpromazine withdrawal 3

Abrupt cessation of antipsychotics like chlorpromazine can precipitate serious movement-related withdrawal symptoms including dyskinesias, parkinsonian symptoms, dystonias, and neuroleptic malignant syndrome, in patients with chronic schizophrenia 2, 3
Insomnia, anxiety, and tensional restlessness are common withdrawal symptoms experienced by chronic schizophrenic patients when switched from low-potency neuroleptics like chlorpromazine, with a prevalence of 85% 2

Gradual withdrawal over a period greater than 1 month is recommended to minimize discontinuation effects, as suggested by the Mayo Clinic guidelines, for patients undergoing chlorpromazine withdrawal 2, 3

Chlorpromazine, a typical antipsychotic, should be tapered or avoided if possible in older adults, particularly when used for behavioral control in cognitive disease, as recommended by the Beers Criteria, due to its anticholinergic properties and potential for cholinergic rebound upon discontinuation 4, 5